(Q42603607)

English

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

scientific article published on June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Michael H Weisman

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Larry W Moreland

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Daniel E Furst

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Michael E Weinblatt

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Edward C Keystone

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Harold E Paulus

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Leah S Teoh

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Raja B Velagapudi

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Peter A Noertersheuser

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

G Richard Granneman

10

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Steven A Fischkoff

11

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Elliot K Chartash

12

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1700-1721

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of treating rheumatoid arthritis: results after 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980164-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80164-9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42603607&oldid=2143289055"